One study stated that IL-4 can augment BCR-signalling and reduce the effectiveness of BCR-kinase inhibitors such as ibrutinib in CLL cells (Blunt et al. 2017). The gene discussed is IL4; the disease is B-cell chronic lymphocytic leukemia.